)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
CompuGroup Medical
CompuGroup Medical (COP) investor relations material
CompuGroup Medical has been delisted
CompuGroup Medical Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary31 Jul, 2025
Executive summary
Strategic partnership with CVC led to a voluntary tender offer, delisting from Frankfurt Stock Exchange as of June 24, 2025, and CVC representation in governance from July 2025.
Gotthardt family remains majority shareholder post-delisting, with CVC as a significant anchor investor and shared board control.
Group revenues reached €576m in H1 2025, up 2% year-over-year, with organic growth of 2% after a decline last year.
Recurring revenue share increased to 76%, and free cash flow doubled to €77m compared to prior year.
Major acquisitions included Farma Point, perimed, Technosanté, and Adour Santé.
Financial highlights
Q2 2025 revenues reached €290m, up 4% year-over-year; H1 2025 revenues at €576m, up 2% year-over-year.
Q2 adjusted EBITDA was €50m (down 6% yoy); H1 adjusted EBITDA €102m (down 11% yoy), margin at 17.6% (down from 20.3%).
Q2 adjusted EPS at €0.30 (prior year: €0.34); H1 adjusted EPS at €0.65–0.66 (prior year: €0.81).
H1 free cash flow improved to €77m from €39m in the prior year, driven by better working capital management.
Consolidated net income for H1 2025 was €16m, down €16m from prior year; tax rate stable at 30%.
Outlook and guidance
2025 guidance projects low to mid-single digit organic revenue growth, slight increase in recurring revenues, and at least slight organic revenue growth in each segment.
Moderate adjusted EBITDA growth anticipated; guidance excludes future acquisitions and is subject to market and FX uncertainties.
Explain the impact of CVC acquisition.
How did the delisting impact strategy?
Why did HIS adjusted EBITDA decrease?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CompuGroup Medical
- 2024 guidance cut after H1 revenue and profit drop, with recurring revenue share up to 75%.COP
Q2 20243 Feb 2026 - Recurring revenues rose to 75% of total as margins and guidance declined amid rising leverage.COPQ3 202416 Jan 2026
- €22.00 per share tender offer at a 51.1% premium, with delisting and innovation focus planned.COPInvestor Update11 Jan 2026
- Recurring revenues rose to 76% of sales as profits fell but cash flow improved.COPQ1 202524 Dec 2025
- Recurring revenues rose 5% to 74% of total as CVC became a key strategic partner.COPQ4 202416 Dec 2025
- AI-powered digital health and recurring revenue drive CGM's growth and margin expansion.COPCMD 202413 Jun 2025
CompuGroup Medical
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage